Targetable FXa-PAR2 signaling promoting monocyte-platelet aggregate formation subverts tumor DNA stimulation of the cGAS-STING-IFN pathway required for T cell priming and efficient checkpoint inhibitor therapy. The gene discussed is STING1; the disease is neoplasm.